Initial clinical experience with oral manganese (CMC-001) for liver MR imaging

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Initial clinical experience with oral manganese (CMC-001) for liver MR imaging. / Thomsen, Henrik S.; Barentsz, Jelle O.; Burcharth, Flemming; Chabanova, Elizaveta; Dekker, Helena M.; Moesgaard, Flemming; Moller, Jakob M.; Leth-Espensen, Per; Logager, Vibeke; Takahashi, Satoru.

In: European Radiology, Vol. 17, No. 1, 01.01.2007, p. 273-278.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Thomsen, HS, Barentsz, JO, Burcharth, F, Chabanova, E, Dekker, HM, Moesgaard, F, Moller, JM, Leth-Espensen, P, Logager, V & Takahashi, S 2007, 'Initial clinical experience with oral manganese (CMC-001) for liver MR imaging', European Radiology, vol. 17, no. 1, pp. 273-278. https://doi.org/10.1007/s00330-006-0336-9

APA

Thomsen, H. S., Barentsz, J. O., Burcharth, F., Chabanova, E., Dekker, H. M., Moesgaard, F., Moller, J. M., Leth-Espensen, P., Logager, V., & Takahashi, S. (2007). Initial clinical experience with oral manganese (CMC-001) for liver MR imaging. European Radiology, 17(1), 273-278. https://doi.org/10.1007/s00330-006-0336-9

Vancouver

Thomsen HS, Barentsz JO, Burcharth F, Chabanova E, Dekker HM, Moesgaard F et al. Initial clinical experience with oral manganese (CMC-001) for liver MR imaging. European Radiology. 2007 Jan 1;17(1):273-278. https://doi.org/10.1007/s00330-006-0336-9

Author

Thomsen, Henrik S. ; Barentsz, Jelle O. ; Burcharth, Flemming ; Chabanova, Elizaveta ; Dekker, Helena M. ; Moesgaard, Flemming ; Moller, Jakob M. ; Leth-Espensen, Per ; Logager, Vibeke ; Takahashi, Satoru. / Initial clinical experience with oral manganese (CMC-001) for liver MR imaging. In: European Radiology. 2007 ; Vol. 17, No. 1. pp. 273-278.

Bibtex

@article{43fa8bc8ed0d468d8f5fb4e50cf4ae1a,
title = "Initial clinical experience with oral manganese (CMC-001) for liver MR imaging",
abstract = "Recently, a new oral liver-specific manganese-based MR agent (CMC-001) has been introduced. This contrast medium is delivered to the liver in high concentrations in the portal vein and very low doses in the hepatic artery, as only small amounts of manganese enter the general circulation. It is taken up by the hepatocytes and excreted in the bile. Our initial experience with the new MR contrast medium in a variety of patients is reported. A total of 20 patients (11 males and 9 females) were studied with MR imaging 2 h after oral ingestion of the contrast agent. Sixteen patients were referred for evaluation of focal liver lesion(s), whereas in the remaining four patients, evaluation of the biliary tract was requested. In the 17 patients without biliary obstruction, there was an increased signal intensity of the liver parenchyma, whereas in the three patients with biliary obstruction, the uptake was delayed. There was excellent visualization of the biliary system on the T1-weighted images in the 16 patients without biliary obstruction referred for evaluation of a focal liver lesion. In seven patients, the uptake was patchy. In patients with focal liver lesions or biliary tract diseases, it is possible to increase the signal intensity of the liver parenchyma after the oral intake of CMC-001. In patients without biliary tract obstruction, the biliary system is easily visualized. Oral manganese seems to be useful in hepatobiliary MRI. Further research is strongly warranted.",
keywords = "Hepatobiliary imaging, Livermetastases, MRI, Oralmanganese",
author = "Thomsen, {Henrik S.} and Barentsz, {Jelle O.} and Flemming Burcharth and Elizaveta Chabanova and Dekker, {Helena M.} and Flemming Moesgaard and Moller, {Jakob M.} and Per Leth-Espensen and Vibeke Logager and Satoru Takahashi",
year = "2007",
month = jan,
day = "1",
doi = "10.1007/s00330-006-0336-9",
language = "English",
volume = "17",
pages = "273--278",
journal = "European Radiology",
issn = "0938-7994",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Initial clinical experience with oral manganese (CMC-001) for liver MR imaging

AU - Thomsen, Henrik S.

AU - Barentsz, Jelle O.

AU - Burcharth, Flemming

AU - Chabanova, Elizaveta

AU - Dekker, Helena M.

AU - Moesgaard, Flemming

AU - Moller, Jakob M.

AU - Leth-Espensen, Per

AU - Logager, Vibeke

AU - Takahashi, Satoru

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Recently, a new oral liver-specific manganese-based MR agent (CMC-001) has been introduced. This contrast medium is delivered to the liver in high concentrations in the portal vein and very low doses in the hepatic artery, as only small amounts of manganese enter the general circulation. It is taken up by the hepatocytes and excreted in the bile. Our initial experience with the new MR contrast medium in a variety of patients is reported. A total of 20 patients (11 males and 9 females) were studied with MR imaging 2 h after oral ingestion of the contrast agent. Sixteen patients were referred for evaluation of focal liver lesion(s), whereas in the remaining four patients, evaluation of the biliary tract was requested. In the 17 patients without biliary obstruction, there was an increased signal intensity of the liver parenchyma, whereas in the three patients with biliary obstruction, the uptake was delayed. There was excellent visualization of the biliary system on the T1-weighted images in the 16 patients without biliary obstruction referred for evaluation of a focal liver lesion. In seven patients, the uptake was patchy. In patients with focal liver lesions or biliary tract diseases, it is possible to increase the signal intensity of the liver parenchyma after the oral intake of CMC-001. In patients without biliary tract obstruction, the biliary system is easily visualized. Oral manganese seems to be useful in hepatobiliary MRI. Further research is strongly warranted.

AB - Recently, a new oral liver-specific manganese-based MR agent (CMC-001) has been introduced. This contrast medium is delivered to the liver in high concentrations in the portal vein and very low doses in the hepatic artery, as only small amounts of manganese enter the general circulation. It is taken up by the hepatocytes and excreted in the bile. Our initial experience with the new MR contrast medium in a variety of patients is reported. A total of 20 patients (11 males and 9 females) were studied with MR imaging 2 h after oral ingestion of the contrast agent. Sixteen patients were referred for evaluation of focal liver lesion(s), whereas in the remaining four patients, evaluation of the biliary tract was requested. In the 17 patients without biliary obstruction, there was an increased signal intensity of the liver parenchyma, whereas in the three patients with biliary obstruction, the uptake was delayed. There was excellent visualization of the biliary system on the T1-weighted images in the 16 patients without biliary obstruction referred for evaluation of a focal liver lesion. In seven patients, the uptake was patchy. In patients with focal liver lesions or biliary tract diseases, it is possible to increase the signal intensity of the liver parenchyma after the oral intake of CMC-001. In patients without biliary tract obstruction, the biliary system is easily visualized. Oral manganese seems to be useful in hepatobiliary MRI. Further research is strongly warranted.

KW - Hepatobiliary imaging

KW - Livermetastases

KW - MRI

KW - Oralmanganese

UR - http://www.scopus.com/inward/record.url?scp=33846062294&partnerID=8YFLogxK

U2 - 10.1007/s00330-006-0336-9

DO - 10.1007/s00330-006-0336-9

M3 - Journal article

C2 - 16763790

AN - SCOPUS:33846062294

VL - 17

SP - 273

EP - 278

JO - European Radiology

JF - European Radiology

SN - 0938-7994

IS - 1

ER -

ID: 222709290